7QT2
 
 | | Antibody FenAb208 - fentanyl complex | | 分子名称: | Antibody heavy chain, Antibody light chain, N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide | | 著者 | Zeelen, J.P, Straaten van, M, Stebbins, C.E. | | 登録日 | 2022-01-14 | | 公開日 | 2023-05-24 | | 最終更新日 | 2024-11-06 | | 実験手法 | X-RAY DIFFRACTION (1.92 Å) | | 主引用文献 | A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl.
Cell Rep, 42, 2023
|
|
7QT4
 | | Antibody FenAb709 - fentanyl complex | | 分子名称: | 2-[2-[2-[2-[[5-oxidanylidene-5-[2-[4-[phenyl(propanoyl)amino]piperidin-1-yl]ethylamino]pentanoyl]amino]ethanoylamino]ethanoylamino]ethanoylamino]ethanoic acid, Antibody heavy chain, Antibody light chain | | 著者 | Zeelen, J.P, Straaten van, M, Stebbins, C.E. | | 登録日 | 2022-01-14 | | 公開日 | 2023-05-24 | | 最終更新日 | 2024-11-13 | | 実験手法 | X-RAY DIFFRACTION (2.32 Å) | | 主引用文献 | A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl.
Cell Rep, 42, 2023
|
|
7QT3
 | | Antibody FenAb609 - fentanyl complex | | 分子名称: | Antibody heavy chain, Antibody light chain, N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide | | 著者 | Zeelen, J.P, Straaten van, M, Stebbins, C.E. | | 登録日 | 2022-01-14 | | 公開日 | 2023-05-24 | | 最終更新日 | 2024-10-23 | | 実験手法 | X-RAY DIFFRACTION (1.7 Å) | | 主引用文献 | A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl.
Cell Rep, 42, 2023
|
|
7QT0
 | | Antibody FenAb136 - fentanyl complex | | 分子名称: | 2-[2-[2-[2-[[5-oxidanylidene-5-[2-[4-[phenyl(propanoyl)amino]piperidin-1-yl]ethylamino]pentanoyl]amino]ethanoylamino]ethanoylamino]ethanoylamino]ethanoic acid, Antibody heavy chain, Antibody light chain | | 著者 | Zeelen, J.P, Straaten van, M, Stebbins, C.E. | | 登録日 | 2022-01-14 | | 公開日 | 2023-05-24 | | 最終更新日 | 2024-10-09 | | 実験手法 | X-RAY DIFFRACTION (2.07 Å) | | 主引用文献 | A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl.
Cell Rep, 42, 2023
|
|
